Full year 2025 product sales

The following table provides the top 20 product net sales from continuing operations in 2025, as well as the change compared with 2024:

Brands
 		Net Sales
(USD m)		% change
(USD)		% change
(cc1)		Brand classification by therapeutic area or established brands
Entresto7,748-1-2Cardiovascular, renal and metabolic
Cosentyx6,66898Immunology
Kisqali4,7835857Oncology
Kesimpta4,4263736Neuroscience
Tafinlar + Mekinist2,21586Oncology
Jakavi2,11097Oncology
Pluvicto1,9944342Oncology
Ilaris1,8832524Immunology
Xolair21,72354Immunology
Promacta/Revolade1,636-26-27Oncology
Scemblix1,2858785Oncology
Zolgensma Group1,23210Neuroscience
Sandostatin Group1,213-5-5Established brands
Leqvio1,1985957Cardiovascular, renal and metabolic
Tasigna1,104-34-34Oncology
Lutathera8161312Oncology
Exforge Group72734Established brands
Lucentis643-38-40Established brands
Diovan Group60422Established brands
Fabhalta3505291287Oncology
  1. For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2025: “—Non-IFRS measures as defined by Novartis.”
  2. Net sales from continuing operations reflect Xolair sales for all indications.
  3. Net sales from continuing operations reflect Fabhalta sales for all indications.